Cover Image
Market Research Report
Product code
913735

Global Vaccine Adjuvants Market, Size, Share, Opportunities and Forecast, 2020-2027

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Vaccine Adjuvants Market, Size, Share, Opportunities and Forecast, 2020-2027
Published: April 3, 2021
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • ALL
  • Description
  • Table of Contents
Description

Global Vaccine Adjuvants Market is segmented By Product (Adjuvant Emulsions, Pathogen Components, Particulate Adjuvants, Combination Adjuvants), By Route of Administration (Oral, Intramuscular, Intranasal, Subcutaneous, Intradermal), By Disease (Cancer and Infectious Diseases), By End User (Research and Commercial Applications), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview

The Global Vaccine Adjuvants Market is expected to grow at a CAGR of 12.5% during the forecasting period (2020-2027).

An adjuvant is an ingredient used in some vaccines to enhance host immune responses in people receiving the vaccine. Vaccines are among the most effective preventative health tools available against infectious diseases, cancer, allergy, and autoimmune diseases. Vaccination aims to generate a strong immune response to the administrated antigen and provide long-term protection against disease. Frequently, using only the antigen is not enough to stimulate that protective immunity. Vaccine adjuvants are compounds that enhance the specific immune responses against co-administered antigens in vaccines.

  • *Source: DataM Intelligence Analysis (2019)

Market Dynamics

The vaccine adjuvants market growth is driven by several factors, such as the high prevalence of infectious diseases, increased government funding for research, and growing focus on preventing diseases.

Globally the incidence of infectious diseases has major health and economic costs. Infectious diseases are caused by bacteria, viruses, parasites, or fungi. Infectious diseases are communicable as well. The number of infectious disease outbreaks has risen steadily in the last 30 years. According to the World Health Organization (WHO), infectious diseases kill more than 17 million people a year. 30 new diseases have emerged in the last 20 years. Vaccines improve immunity to a particular disease and are a vital part of infectious disease prevention. One of the most cost-effective investments in health and economic development WHO estimates that 1.5 million children under the age of five lose their lives to vaccine-preventable diseases every year.

Many government agencies are working towards new research in vaccine adjuvants and raising enough funds for the new advancements. National Institute of Allergy and Infectious Diseases (NIAID) support aspects of adjuvant research. NIAID recognized opportunities to develop novel adjuvants or modify existing adjuvants to trigger long-term protective immunity and durable vaccine efficacy safely. In 2010, NIAID prepared its first Strategic Plan for Research on Vaccine Adjuvants and convened an Adjuvant Blue Ribbon Panel (BRP) to review the plan. Furthermore, National Biopharma Mission, in collaboration with NIAID, is providing research grants for the discovery, development, and/or preclinical testing of vaccine adjuvants under the aegis of Indo US Vaccine Action Programme (VAP).  VAP is one of the oldest bilateral programs that support a wide range of collaborative activities related to immunology, infectious disease biology, and vaccine research.

Market Segmentation

The global vaccine adjuvants market is segmented into adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and others by product type. Emulsion-based adjuvants are oil-in-water or water-in-oil emulsions, which work to enable the slow release of an antigen at the injection site. MF59 and AS03 are two licensed oil-in-water emulsion adjuvant used in humans. MF59 is not toxic and prepared with a low squalene content, a biodegradable oil naturally found in plants and animals, including humans. Pathogen-based vaccine adjuvants are adjuvants that are derived from different pathogens. Bacteria have an abundance of capacity for stimulating the immune system, and the adjuvants derived from bacteria are abundant. As whole bacteria are generally too toxic to use as an adjuvant, many bacterium-derived vaccine adjuvants are derived from parts of bacteria. Only two of the pathogen-based adjuvants are licensed. One is MPL licensed in the U.S. as part of the AS04 adjuvant formulation, and Bordetella pertussis component vaccine adjuvant is used in several licensed vaccines. Particulate antigen delivery systems are adjuvants that have a depot effect for the antigen and include liposomes, polymeric microspheres, virus-like particles, and immunostimulating complexes. These adjuvants act as vehicles for the antigen while often also containing immunostimulating compounds. Combination vaccine adjuvants include two or more different adjuvants that are used in combination. Examples of combination adjuvants include adjuvants such as AS04 and Algammulin. These adjuvants combine different mechanisms of action from two or more adjuvants.

Among these, particulate adjuvants are expected to hold the dominant market share over the period of forecast (2020-2027). Particulate type adjuvants consist of alum, virosomes, and cytokines. Alum is the most commonly used and the most efficient adjuvant consisting of aluminum salts. It is found in numerous vaccines, including diphtheria-tetanus-pertussis, human papillomavirus, and hepatitis vaccines.

The market is segmented into oral, intramuscular, intranasal, subcutaneous, and intradermal by route of administration. Among these, intramuscular is expected to hold the highest market share during the forecast period (2020-2027) due to a large number of adjuvants being effective only when taken intramuscularly, such as alum adjuvants. Alum adjuvants have the highest market share, and they are only effective with the intramuscular route of administration.

Based on disease type, the market is segmented into cancer, infectious diseases, and others. Among these infectious diseases, the segment is expected to hold the largest market share over the period of forecast (2020-2027) due to the rising prevalence of infectious diseases globally as an epidemic. Many new infectious diseases have been discovered in the last 20 years, such as Ebola, Zika, and many more. Vaccines are the most efficient treatment for infectious diseases.

By end-users, the market is segmented as pharmaceutical and biotech companies, research institutes, and others. Pharmaceutical and biotech companies are expected to be the largest shareholder in the market over the period of forecast (2020-2027). Many new companies and existing companies in the market segment are working for new research in the area of vaccine adjuvants. This is due to large government funding for new research and development of technology.

Geographical Analysis

North America is dominating the vaccine adjuvants market in 2018 and estimated to hold the largest market size over the forecast period (2020-2027), owing to the highly aware public, favorable government initiatives and policies, and an increase in research and development. The US government supports vaccine adjuvants through various government bodies, like the National Institute of Allergy and Infectious Diseases, which supports the work on new research and development, and provides funds to different countries through its parent organization National Institute of Health (NIH). NIH is collaborating with many research institutes and universities to fasten up the research of new vaccine adjuvants. Many companies present in the region are also developing many new vaccine adjuvants. There is a presence of many major companies in the region that focus on the parent region.

Competitive Landscape

Some of the major key players in the market are Croda International Plc, CSL Limited, SEPPIC, Agenus, Inc., Novavax, Inc., SPI Pharma, Inc., Invivogen, Avanti Polar Lipids, Inc., Valneva, and OZ Biosciences.

In the vaccine adjuvants market, the key players are adopting various growth strategies such as new product launches, partnerships, and collaborations with multiple research institutes and increasing research and development and high investment, contributing to the growth of the vaccine adjuvants market globally.

Why Purchase the Report?

Visualize the composition of the vaccine adjuvants market across each indication, in terms of type and by type highlighting the key commercial assets and players.

Identify commercial opportunities in vaccine adjuvants by analyzing trends and co-development deals.

Excel data sheets with thousands of data points of vaccines adjuvants market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key products of all major market players.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

Table of Contents

Table of Contents

Vaccine Adjuvants Market Methodology and Scope

Research Methodology

Research Objective and Scope of the Report

Vaccine Adjuvants Market - Market Definition and Overview

Vaccine Adjuvants Market - Executive Summary

Market Snippet by Product Type

Market Snippet by Route of Administration

Market Snippet by Diseases

Market Snippet by End User

DataM CLO Scenario

Vaccine Adjuvants Market-Market Dynamics

Market Impacting Factors

Drivers

Increasing prevalence of infectious and zoonotic diseases.

Increasing use of Adjuvants in vaccine

Restraints

High costs of research

Stringent regulatory policies

Impact Analysis

Vaccine Adjuvants Market - Industry Analysis

Porter's Five Forces Analysis

Supply Chain Analysis

Regulatory Analysis

Pricing Analysis

Design Advances

Key Companies to Watch

Epidemiology

Vaccine Adjuvants Market - By Product Type

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

Market Attractiveness Index, By Product Type

Adjuvant Emulsions

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Pathogen Components

Particulate Adjuvants

Combination Adjuvants

Others

Vaccine Adjuvants Market - By Route of Administration

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

Market Attractiveness Index, By Route of Administration

Oral

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Intramuscular

Intranasal

Subcutaneous

Intradermal

Others

Vaccine Adjuvants Market - By Diseases

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diseases

Market Attractiveness Index, By Diseases

Cancer

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Infectious diseases

Vaccine Adjuvants Market - By End User

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.

Market Attractiveness Index, By End User

Pharmaceutical companies

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Research Institutes

Others

Vaccine Adjuvants Market- By Region

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

Market Attractiveness Index, By Region

North America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diseases

Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

The U.S.

Canada

Mexico

Europe

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diseases

Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Germany

The U.K.

France

Italy

Spain

Rest of Europe

South America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diseases

Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Brazil

Argentina

Rest of South America

Asia-Pacific

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diseases

Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

China

India

Japan

Australia

Rest of Asia Pacific

The Middle East and Africa

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diseases

Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.

Market - Competitive Landscape

Competitive Scenario

Competitor Vaccine Adjuvants Strategy Analysis

Comparative Drug Portfolio Analysis

Market Positioning/Share Analysis

Mergers and Acquisitions Analysis

Company Profiles

InvivoGen

Company Overview

Drug Portfolio and Description

Key Highlights

Financial Overview

OZ Biosciences

Sigma-Aldrich Co. LLC

SEPPIC

SPI Pharma

Agenus, Inc

Aphios Corp

VaLiant LLC

Vaxine Pty Ltd

Kineta, Inc

Vaccine Adjuvants Market- Premium Insights

Vaccine Adjuvants Market- DataM

Appendix

About Us and Services

Contact Us